Key result
Maternal serum VEGF levels were significantly lower in women with abnormally invasive placenta and predicted the condition better than NT-proBNP (AUC 0.729).
Why the study?
It was unknown whether maternal serum VEGF or NT-proBNP better predicts abnormally invasive placenta and the degree of invasion.
Does maternal serum VEGF or NT-proBNP predict abnormally invasive placenta in pregnant women?
Case-Control (n=99)
Single-blind
Yes
Does maternal serum VEGF or NT-proBNP predict abnormally invasive placenta in pregnant women?
Maternal serum VEGF levels are significantly decreased in abnormally invasive placenta and, when combined with previous cesarean deliveries, provide high predictive value for its occurrence.
Answers are grounded in this paper and cite their sources.
Suggests VEGF may serve as a novel biomarker for abnormally invasive placenta; leaves open whether.
The aim of this study was to test if maternal serum vascular endothelial growth factor (VEGF) or N-terminal pro B-type natriuretic peptide (NT-proBNP) predicts abnormally invasive placenta (AIP) better. Secondary objective was to test whether the serum levels of VEGF and NT-proBNP can predict the degree of invasion. In a multicenter case-control study design, gestational age-matched serum samples from pregnant women with AIP (n = 44) and uncomplicated pregnancies (n = 55) who had been enrolled at Charité - Universitätsmedizin Berlin, Germany and Centre Hospitalier Régional de la Citadelle in Liège, Belgium were analyzed. Maternal blood serum VEGF and NT-proBNP levels were immunoassayed from samples taken immediately before delivery (GA median: 35 weeks). Biomarker levels were compared between AIP and control group. The correlation of biomarker levels with the clinical AIP degree was assessed. The predictive biomarker ability was characterized through a multivariate regression model and receiver operating characteristic curves. Women with AIP had significantly lower maternal serum VEGF levels (AIP mean 285 pg/ml, 95% CI 248-322, vs. control: 391 pg/ml, 95% CI 356-426, p < 0.01) and higher NT-proBNP levels (AIP median 329 pg/ml, IQR 287-385, vs. control 295 pg/ml, IQR 273-356, p = 0.03). Maternal serum VEGF levels were able to predict AIP better (AUC = 0.729, 0.622-0.836, p < 0.001; VEGF + number of previous cesarean deliveries: AUC = 0.915, 0.853-0.977, p < 0.001). Maternal serum VEGF levels correlated inversely with the clinical AIP degree (r = - 0.32, p < 0.01). In short, maternal serum VEGF, more than NT-proBNP, can help in predicting AIP and hints at the degree of invasion.
No takes yet. Share an insight, caveat, or question.
Schwickert et al. (2020) conducted a case-control in Abnormally invasive placenta (AIP) (n=99). Maternal serum VEGF and NT-proBNP levels vs. Normal placentation (uncomplicated pregnancies) was evaluated on Prediction of abnormally invasive placenta (AIP) using maternal serum VEGF levels (AUC 0.729, 95% CI 0.622-0.836, p=<0.001). Maternal serum VEGF levels were significantly lower in women with abnormally invasive placenta and predicted the condition better than NT-proBNP (AUC 0.729).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: